LA JOLLA, Calif., April 30, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Bruce Carter, Ph.D. to its Board of Directors. Dr. Carter currently serves as an independent member of the Board of Directors of Immune Design Corp., a privately held biotech company located in Seattle, and as a board member of additional scientific organizations. He previously served as Chief Executive Officer of Zymogenetics, Inc. and has over 20 years of pharmaceutical and biotech drug development experience.
"We are delighted to have Bruce join our Board," said John Maraganore, Ph.D., Chairman of the Board of Directors of Regulus Therapeutics Inc. "His impressive credentials and sound business judgment will further enhance our Board's collective expertise."
"Regulus' mature therapeutic platform targeting microRNAs, coupled with its world-renowned scientific advisors and experienced leadership team, make joining the Board an exciting opportunity for me," said Dr. Carter. "I look forward to service on the Board as Regulus drives multiple programs toward the clinic."
Dr. Carter joined Immune Design Corp. in November 2009 and served as Executive Chairman of the Board until May 2011, and Chairman of the Board until February 2012. He still serves as an independent Director. In addition to his duties at Immune Design, Dr. Carter serves as Chairman of the Board of the TB Alliance, a worldwide nonprofit organization based in New York City, and Xencor, Inc., in Pasadena, California. He also serves as a Board member for Dr. Reddy, Ltd. located in Hyderabad, India and QLT, Inc. of Vancouver, B.C., Canada.
Prior to joining Regulus' Board of Directors, Dr. Carter was a member of the management team at ZymoGenetics, Inc. where he held vari
|SOURCE Regulus Therapeutics Inc.|
Copyright©2010 PR Newswire.
All rights reserved